Yi-Ming Yuan1, Li Luo2, Zhen Guo3, Ming Yang2, Ren-Song Ye4, Chuan Luo2. 1. Department of Geriatric Medicine, West China Hospital, Sichuan University, China yym28tb@163.com. 2. Department of Geriatric Medicine, West China Hospital, Sichuan University, China. 3. ENT Department, Pixian TCM Hospital, China. 4. Department of Internal Medicine, The Affiliated Shanghai Eighth People's Hospital of Jiangsu University,Shanghai, China.
Abstract
OBJECTIVES: To explore the role of the renin-angiotensin-aldosterone system (RAAS) in the pathogenesis of pulmonary arterial hypertension (PAH) induced by chronic exposure to cigarette smoke. METHODS: 48 healthy male SD rats were randomly divided into four groups (12/group): control group (group A); inhibitor alone group (group B); cigarette induction group (group C); cigarette induction + inhibitor group (group D). After the establishment of smoking-induced PAH rat model, the right ventricular systolic pressure (RVSP) was detected using an inserted catheter; western blotting was used to detect the protein expression of angiotensin-converting enzyme-2 (ACE2) and angiotensin-converting enzyme (ACE); expression levels of angiotensin II (AngII) in lung tissue were measured by radioimmunoassay. RESULTS: After six months of cigarette exposure, the RVSP of chronic cigarette induction group was significantly higher than that of the control group; expression levels of AngII and ACE increased in lung tissues, but ACE2 expression levels reduced. Compared with cigarette exposure group, after losartan treatment, RVSP, ACE and AngII obviously decreased (P<0.05), and ACE2 expression levels significantly increased. CONCLUSION: Chronic cigarette exposure may result in PAH and affect the protein expression of ACE2 and ACE in lung tissue, suggesting that ACE2 and ACE play an important role in the pathogenesis of smoking-induced PAH.
OBJECTIVES: To explore the role of the renin-angiotensin-aldosterone system (RAAS) in the pathogenesis of pulmonary arterial hypertension (PAH) induced by chronic exposure to cigarette smoke. METHODS: 48 healthy male SD rats were randomly divided into four groups (12/group): control group (group A); inhibitor alone group (group B); cigarette induction group (group C); cigarette induction + inhibitor group (group D). After the establishment of smoking-induced PAHrat model, the right ventricular systolic pressure (RVSP) was detected using an inserted catheter; western blotting was used to detect the protein expression of angiotensin-converting enzyme-2 (ACE2) and angiotensin-converting enzyme (ACE); expression levels of angiotensin II (AngII) in lung tissue were measured by radioimmunoassay. RESULTS: After six months of cigarette exposure, the RVSP of chronic cigarette induction group was significantly higher than that of the control group; expression levels of AngII and ACE increased in lung tissues, but ACE2 expression levels reduced. Compared with cigarette exposure group, after losartan treatment, RVSP, ACE and AngII obviously decreased (P<0.05), and ACE2 expression levels significantly increased. CONCLUSION: Chronic cigarette exposure may result in PAH and affect the protein expression of ACE2 and ACE in lung tissue, suggesting that ACE2 and ACE play an important role in the pathogenesis of smoking-induced PAH.
Pulmonary arterial hypertension (PAH ) is a disease of pulmonary vascular resistance
increase caused by a variety of factors, ultimately leading to right ventricular
failure.[1] Animal experiments demonstrated that chronic cigarette exposure
may cause lung parenchyma and airway inflammation, and induce the reconstruction of
small pulmonary vessels and small airway, resulting in pulmonary arterial
hypertension.[2,3]
Previous studies have reported that activation of the renin–angiotensin–aldosterone
system (RAAS) system was involved in the pathogenesis of pulmonary vascular
remodeling and PAH.[4,5]
The expression of angiotensin-converting enzyme (ACE) increased in the pulmonary
arterial of patients with PAH.[5] RAAS system activation and
increased AngII levels were observed in PAHrats induced by hypoxia and
monocrotaline,[6] and the expressions of AngII and AngII type 1 receptor
(AT1R) were also increased in vivo.[7] In addition, treatment with ACEI
or AT1R inhibitors can relieve the pulmonary vascular remodeling and PAH, and
improve endothelial function in hypoxia- monocrotaline-treated rats.[8]In the RAAS system, the key role of ACE is to promote Ang I to generate AngII. ACE2
is a regulating member of RAAS system discovered in recent years, with a key role in
the pathway of AngII–Ang generation (1–7).[9] ACE and ACE2 may have opposite
physiological effects; ACE2 is the specific negative regulatory mechanism after RAAS
system activation.[9-11] ACE2 has been
suggested to be associated with the severe acute respiratory syndrome caused by
coronavirus infection, acute lung injury, pulmonary fibrosis and PAH induced by
monocrotaline. A recent study showed that the antihypertensive effect of AT1R was
partly due to the increased metabolic AngII by ACE2.[8] Therefore, the present study
aimed to investigate whether ACE2 and ACE have effects on the PAH induced by chronic
cigarette exposure, further exploring the exact mechanism of chronic cigarette
smoking-induced PAH.
Materials and methods
Experimental animals
The present study was approved by the Ethical Committee of West China Hospital,
Sichuan University. 48 male Sprague–Dawley rats (200~250g) were randomly divided
into four groups (12/group): control group (group A); inhibitor group (group B);
cigarette induction group (group C); cigarette induction + inhibitor group
(group D).Cigarette exposure scenarios[12]: rats in cigarette exposure group passively
received exposure to cigarette smoking in a standard toxicological box, igniting
15 cigarettes (each containing 14 mg tar and 1.0 g nicotine), twice per day for
30 min; the control group was exposed to fresh air in a same kind of
toxicological box at the same time; inhibitor losartan was injected
intraperitoneally daily at a dose of 10 mg/kg.d-1. Normal control
group daily received equal saline injection for six months.
Pulmonary artery pressure measurements and morphological analysis
After six months of observation, rats were anesthetized by intraperitoneal
injection of pentobarbital (50 mg/kg) and fixed in supine position, breathing
room air; the right chest was exposed to make a ‘V’ notch; with heparin (50 U/ml
) anticoagulation, the silicone tube (0.45 mm ID, 0.8mm OD) was inserted into
the right ventricle through the right atrium; the other end of the catheter was
connected to a P23×L pressure sensor; after treated by the carrier amplifier,
the pressure was recorded by Gould-34008/DASA4600 physiology record instrument.
After detection of the right ventricular systolic pressure (RVSP), lung tissues
of all rats were collected and fixed in 4% paraformaldehyde, and then the lungs
were paraffin-embedded overnight and sliced, histological staining; the left
lungs were stored in a -80°C refrigerator for biochemical analysis. Paraffin
sections were placed in murine ACE2 polyclonal antibody (Santa Cruz, Texas, USA)
for immunohistochemical staining to observe the ACE2 protein expression. An
optical microscope (H600, Nikon, and Tokyo, Japan) and a radioisotope dynamic
digital camera (Nikon, Tokyo, Japan) were used to collect images.
AngII in lung measured by radioimmunoassay
AngII radioimmunoassay kit (Beijing Nonth Institute of Biological Technology,
Beiiing, China) was used to measure the expression levels of AngII: the lung
tissue was washed with ice-saline and chopped; and then it was heated in 0.1 M
HCl at 100°C for 10 min and homogenized. After centrifugation at 15,000×g for 30
min, the supernatant was freeze-dried and re-dissolved in 400μl buffer; the
radioactivity was measured by a γ counter.
ACE2 and ACE protein levels in lung tissue detected by western blot
Protein expressions of ACE2 and ACE were detected by western blot. Lung
homogenate solution was mixed with the tissue lysate (Roche Apphed Sciece,
Indianapolis, USA) containing 50 mM of Tris-HCl, 150 mM of NaCl, 1% of NP-40,
0.5% of sodium deoxycholate, 2 mM of NaF, 2 mM of EDTA, 0.1% of SDS and protease
inhibitors. The protein concentration of lung homogenates was measured using BCA
assay (Pierce. Rockford, IL, USA). Equal amounts of protein samples (30μg) were
separated using 10% of polyacrylamide gel and transferred to a 0.45μM of
polyvinylidene fluoride (PVDF) membrane (Millipore, Bedford, MA). Membranes were
incubated with ACE2 polyclonal antibody (1:500; Santa Cruz Biotechnologies,
Santa Cruz, CA). Referring to the manual operation, western blot was performed
using enhanced chemiluminescence.
Statistical methods
SPSS 17.0 was used for statistical analysis. Measurement data were expressed as
mean±SD; differences between groups were compared using one-way analysis of
variance. P<0.05 was considered statistically
significant.
Results
Increased RVSP by cigarette smoke induction
After six months of cigarette exposure the RVSP of rats significantly increased
(Figure 1); losartan
can significantly reduce the increased RVSP caused by smoking, suggesting that
losartan may relieve chronic smoking-induced PAH.
Figure 1.
Smoking-induced increased right ventricular systolic pressure in rats.
Y-axis: RVSP level (mmHg).
Compared to group A, *P<0.05; compared to group C,
**P<0.05.
Smoking-induced increased right ventricular systolic pressure in rats.
Y-axis: RVSP level (mmHg).Compared to group A, *P<0.05; compared to group C,
**P<0.05.
Increased Ang II caused by cigarette smoke exposure and therapeutic effects
of losartan
We have detected AngII concentrations in lung tissues by radioimmunoassay after
six months of exposure to cigarette. As shown in Figure 2, expression levels of AngII in
the lung tissues of rats in chronic cigarette exposure group were significantly
increased, but was significantly inhibited by losartan
(P<0.05).
Figure 2.
Smoking-induced increased Ang II concentration in rats. Y-axis: Ang II
concentration (μg/mg protein).
Compared to group A, *P<0.05; compared to group C,
**P<0.05.
Smoking-induced increased Ang II concentration in rats. Y-axis: Ang II
concentration (μg/mg protein).Compared to group A, *P<0.05; compared to group C,
**P<0.05.
Increased ACE and decreased ACE2 caused by cigarette-induced PAH and the
therapeutic effects of losartan
To further explore the increasing mechanism of AngII in smoking-induced PAHrats,
we examined the expression levels of ACE and ACE2 in the cigarette exposure
group. Western blot was used to detect ACE and ACE2 protein expressions, and the
expression levels of ACE2 were also detected by a immunohistochemical staining
method. Immunohistochemistry showed that compared with the control group, the
lung section positive staining showed that the cigarette exposure group had a
significant reduction in ACE2 expression (Figure 3).
Figure 3.
ACE2 expression in lung tissue sections by immunohistochemical detection
(×100). (a) control group (group A); (b)inhibitor alone group (group B);
(c) cigarette induction group (group C); (d) cigarette induction +
inhibitor group (group D).
ACE2 expression in lung tissue sections by immunohistochemical detection
(×100). (a) control group (group A); (b)inhibitor alone group (group B);
(c) cigarette induction group (group C); (d) cigarette induction +
inhibitor group (group D).Western blotting analysis showed that cigarette exposure significantly increased
the ACE levels in lung and reduced ACE2 levels (Figure 4). Losartan treatment could
significantly increase ACE2 levels, and it was also found that the expression
levels of ACE decreased in cigarette exposure group and cigarette exposure +
losartan group, indicating that the smoking-induced expressions of ACE2 and ACE
can be reversed to some extent by losartan.
Figure 4.
ACE2 and ACE expression in lung tissue by western blotting.
Compared to group A, *P<0.05; compared to group C,
**P<0.05.
ACE2 and ACE expression in lung tissue by western blotting.Compared to group A, *P<0.05; compared to group C,
**P<0.05.
Discussion
Smoking reduces the immune response of the host defense. Smoke-mediated oxidative
stress response can stimulate the release of pro-inflammatory cytokines, and induce
inflammatory response.[12] Selman et al.[13] reported that smoking may act
directly on the vascular system, affecting the release of vascular regulation
factor, thus regulating vascular contraction and relaxation and the proliferation of
vascular smooth muscle. Eventually, it leads to increased vascular resistance and
pulmonary artery pressure which is caused by the remodeling of pulmonary arterioles,
arteries and micro arteries.[6-8]This study confirmed that chronic cigarette-smoke exposure significantly increased
RVSP in rats, which was significantly reduced by losartan. Mean pulmonary arterial
hypertension and increased pulmonary vascular muscle degrees were also observed in
rats exposed to cigarette smoke for 16 weeks.[14] Our findings were consistent
with the above study; cigarette exposure for six months can significantly increase
RVSP in rats. In summary, chronic cigarette smoke may directly lead to the pulmonary
artery remodeling and PAH. In recent years, it has been found that exposure to
nicotine (the main component of cigarette smoke) can increase both the expression
and activity of ACE in human endothelial cells.[15] ACE plays a key role in the
RAAS system, which can convert Ang I to AngII; cigarette smoke exposure can activate
the RAAS system to increase AngII levels. The major physiological and
pharmacological effects of AngII are mediated by AT1R,[16] and it has been confirmed that
AngII plays an important role in PAH by binding to AT1R.[16] This study suggested that the
pathogenesis of cigarette-induced PAH also involves the activation of the RAAS
system. We found that compared with the control group, PAHrats exposed to cigarette
smoke for six months had a reduction in ACE2 expression and an increased expression
of ACE and AngII (almost double). In the RAAS system, ACE decomposes Ang I to
generate potent vasoconstrictor and ACE2 hydrolyzes Ang I to generate a negative
regulatory protein Ang (1–7).[9] In previous study, Karram et al.[17] found that losartan therapy
affected plasma ACE protein expression in normotensive rats. Some experiments have
confirmed that losartan can effectively increase ACE2 activity and its protein
expression in rat myocardium or human kidney. Increased ACE2 can accelerate the
conversion of AngII to Ang (1–7) to reduce the concentration of AngII.[18-19] This study
found that after six months of exposure to cigarette, ACE2 protein expression was
significantly reduced and pulmonary artery pressure was increased significantly in
rat lungs.In conclusion, chronic cigarette smoke exposure induced a significant increasing in
RVSP, AngII levels and ACE protein expression in lung tissue, but decreased ACE2
expression. Losartan treatment can effectively reduce the degree of PAH and reverse
the increased AngII and ACE expression, indicating that losartan can not only
inhibit the effect of AngII in the lung tissue of cigarette smoke-induced PAHrats,
but can also reduce the levels of AngII. ACE and ACE2 play roles in chronic
cigarette smoke-induced PAH by regulating AngII expression.
Authors: Mike O Becker; Angela Kill; Marissa Kutsche; Jeannine Guenther; Angelika Rose; Christoph Tabeling; Martin Witzenrath; Anja A Kühl; Harald Heidecke; Hossein A Ghofrani; Henning Tiede; Ralph T Schermuly; Nils Nickel; Marius M Hoeper; Ivo Lukitsch; Maik Gollasch; Wolfgang M Kuebler; Sebastian Bock; Gerd R Burmester; Duska Dragun; Gabriela Riemekasten Journal: Am J Respir Crit Care Med Date: 2014-10-01 Impact factor: 21.405
Authors: Salvatore Rosanio; Francesco Pelliccia; Carlo Gaudio; Cesare Greco; Abdul M Keylani; Darrin C D'Agostino Journal: Biomed Res Int Date: 2014-06-12 Impact factor: 3.411
Authors: Joshua M Oakes; Robert M Fuchs; Jason D Gardner; Eric Lazartigues; Xinping Yue Journal: Am J Physiol Regul Integr Comp Physiol Date: 2018-08-08 Impact factor: 3.619
Authors: Nicholas D Fried; Tamara M Morris; Anna Whitehead; Eric Lazartigues; Xinping Yue; Jason D Gardner Journal: Am J Physiol Heart Circ Physiol Date: 2021-02-12 Impact factor: 4.733
Authors: Joshua M Oakes; Jiaxi Xu; Tamara M Morris; Nicholas D Fried; Charlotte S Pearson; Thomas D Lobell; Nicholas W Gilpin; Eric Lazartigues; Jason D Gardner; Xinping Yue Journal: Hypertension Date: 2020-03-16 Impact factor: 10.190